Eikon aims high for NASDAQ listing: Public Equity Report

Two companies aspiring to reach NASDAQ have proposed terms for their IPOs, setting the stage for more closely-watched listings that could arrive next week.

Eikon Therapeutics Inc., the start-up led by former Merck & Co. Inc. (NYSE:MRK) EVP Roger Perlmutter, is aiming for the larger offering, with terms suggesting it could raise $300 million at the midpoint of its proposed range. The Millbrae, Calif.-based company is advancing in-licensed candidates as well as molecules developed internally using its single-molecule tracking technology, based in part on advances in microscopy...